PSIL.US AdvisorShares Psychedelics ETF
- Total assets
- 38.1M
- Expense ratio
- 0.99%
- Dividend yield
- 7.99%
- 1-year return
- +6.92%
- Holdings
- 23
- Since
- 2021
Fund data as reported by the issuer, updated Nov 17, 2026. Total assets are in the fund's base currency.
What does PSIL.US invest in?
- Mostly US stocks (68.9%)
- Largest sector: Healthcare (100.0%)
- Largest region: North America (84.9%)
- Top 3 holdings: 31.4% of the fund
Asset allocation
- US stocks 68.9%
- Non-US stocks 29.3%
- Cash 0.3%
Top holdings
- Definium Therapeutics, Inc. 12.06%
- Compass Pathways Plc 10.99%
- Helus Pharma Inc. 8.36%
- Eli Lilly and Company 6.65%
- Relmada Therapeutics Inc 6.55%
AdvisorShares Psychedelics ETF performance
Sharpe ratio 0.46- This year
- +2.61%
- 1 year
- +6.92%
- 3 years
- +14.27%
- 5 years
- -23.71%
Volatility 27.0% over 1 year and 47.0% over 3 years. High: expect large swings.
Total returns in the fund's currency as reported by the issuer; past returns do not predict future returns. Volatility is the yearly standard deviation of returns. Ask AI to explain these numbers
PSIL.US price
Prices on the chart can differ slightly from the closing prices StockSummer shows.
About AdvisorShares Psychedelics ETF
The fund is an actively managed ETF that seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that derive at least 50% of their net revenue from or devote 50% of their assets to psychedelic drugs and derivatives that have economic characteristics similar to such securities. The fund primarily invests in publicly listed life sciences companies…
Full fund profileAdvisorShares Psychedelics ETF top holdings
72.2% of the fund| Holding | Sector | Country | Weight |
|---|---|---|---|
| Definium Therapeutics, Inc. DFTX.US | Healthcare | United States | 12.06% |
| Compass Pathways Plc CMPS.US | Healthcare | United States | 10.99% |
| Helus Pharma Inc. HELP.NEO | Healthcare | Canada | 8.36% |
| Eli Lilly and Company LLY.US | Healthcare | United States | 6.65% |
| Relmada Therapeutics Inc RLMD.US | Healthcare | United States | 6.55% |
| Neurocrine Biosciences Inc NBIX.US | Healthcare | United States | 6.28% |
| AbbVie Inc ABBV.US | Healthcare | United States | 6.20% |
| Alto Neuroscience, Inc. ANRO.US | Healthcare | United States | 5.20% |
| Seaport Therapeutics, Inc. Common Stock SPTX.US | Healthcare | United States | 5.05% |
| Indivior PLC Ordinary Shares INDV.US | Healthcare | United States | 4.89% |
The 10 largest of 23 holdings.
PSIL.US sector exposure
- Healthcare100.0%
Share of the stocks in the fund.
PSIL.US regional exposure
- North America84.9%
- United Kingdom10.0%
- Europe Developed5.0%
- Australasia0.7%
Share of the stocks in the fund.
Company size
Average market cap 5.00B- Mega cap7.2%
- Big cap11.8%
- Small cap22.2%
- Micro cap36.8%
AdvisorShares Psychedelics ETF fund profile
- Fund name
- AdvisorShares Psychedelics ETF
- Ticker
- PSIL.US
- Exchange
- USA Stocks
- Issuer
- AdvisorShares
- Index tracked
- -
- Category
- -
- Inception date
- Sep 15, 2021
- Trading currency
- USD
- Expense ratio
- 0.99%
- Annual turnover
- 0.7%
About AdvisorShares Psychedelics ETF
The fund is an actively managed ETF that seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that derive at least 50% of their net revenue from or devote 50% of their assets to psychedelic drugs and derivatives that have economic characteristics similar to such securities. The fund primarily invests in publicly listed life sciences companies focused on psychedelic medicines as well as other companies with activities in the psychedelics business. The fund is non-diversified.